Marathon Pharmaceuticals will temporarily halt the rollout of a drug to treat genetic muscle deterioration after facing criticism over their plan to charge $89,000 a year for a drug that's widely available abroad for about $1,000 a year.
The just-departed commissioner of the Food and Drug Administration has concerns about plans to speed up drug approvals and dramatically reduce regulations at the agency, as advocated recently by President Donald Trump.
The Trump administration has thrown its weight behind giving patients the “right to try” experimental drugs outside clinical trials. While such laws purport to offer hope for the dying, they will actually slow medical progress.
Complications from warfarin can be serious. According to one study published in 2011, it is implicated in 33% of adverse drug events in patients 65 or older, and nearly all of those events are from unintentional overdoses.
Profits were relatively stable at Cardinal Health in the second quarter, but executives at the distribution giant said they are beginning to see a return to normal generic drug-pricing trends as a result of increased competition.
Per-person prescription drug spending increased 3.8% for health plans covering employees and their families, a tame increase when compared to the year before, according to a new report from Express Scripts.
ID Genomics intends to allow physicians to quickly detect specific types of UTIs and the best antibiotics to treat them. “It is like we are creating a criminal dossier of bacterial strains,” says the startup's founder, Dr. Evgeni Sokurenko.
Trump told pharmaceutical leaders at the White House that he wants to reduce drug prices, pare back regulations and increase drug manufacturing in the U.S. But he seemed to back away from his support for Medicare negotiating prices.
A malaria drug is doing something it's never done before: treat brain cancer.
President Donald Trump has signed an order withdrawing the U.S. from the Trans-Pacific Partnership that has been contested by both healthcare companies and activists.
A notable brand name competitor to the EpiPen will be available for purchase in early February, with a pricing strategy that's great for patients but may upset insurers.
The Obama administration is using its last few days in office to address a number of data privacy issues—most recently releasing a final rule that lifts a burden on scientists working with human subjects.